The National Lung Matrix Trial: Translating the Biology of Stratification in Advanced Non-small-cell Lung Cancer

Overview

Journal Ann Oncol

Publisher Elsevier

Specialty Oncology

Date 2015 Sep 28

PMID 26410619

Citations 30

Authors

G Middleton

L R Crack

S Popat

C Swanton

S J Hollingsworth

R Buller

I Walker

T H Carr

D Wherton

L J Billingham

Affiliations

Soon will be listed here.

Abstract

Background: The management of NSCLC has been transformed by stratified medicine. The National Lung Matrix Trial (NLMT) is a UK-wide study exploring the activity of rationally selected biomarker/targeted therapy combinations.

Patients And Methods: The Cancer Research UK (CRUK) Stratified Medicine Programme 2 is undertaking the large volume national molecular pre-screening which integrates with the NLMT. At study initiation, there are eight drugs being used to target 18 molecular cohorts. The aim is to determine whether there is sufficient signal of activity in any drug-biomarker combination to warrant further investigation. A Bayesian adaptive design that gives a more realistic approach to decision making and flexibility to make conclusions without fixing the sample size was chosen. The screening platform is an adaptable 28-gene Nextera next-generation sequencing platform designed by Illumina, covering the range of molecular abnormalities being targeted. The adaptive design allows new biomarker-drug combination cohorts to be incorporated by substantial amendment. The pre-clinical justification for each biomarker-drug combination has been rigorously assessed creating molecular exclusion rules and a trumping strategy in patients harbouring concomitant actionable genetic abnormalities. Discrete routes of pathway activation or inactivation determined by cancer genome aberrations are treated as separate cohorts. Key translational analyses include the deep genomic analysis of pre- and post-treatment biopsies, the establishment of patient-derived xenograft models and longitudinal ctDNA collection, in order to define predictive biomarkers, mechanisms of resistance and early markers of response and relapse.

Conclusion: The SMP2 platform will provide large scale genetic screening to inform entry into the NLMT, a trial explicitly aimed at discovering novel actionable cohorts in NSCLC.

Clinical Trial Isrctn: 38344105.

Citing Articles

Targeting the PI3K/AKT/mTOR pathway in lung cancer: mechanisms and therapeutic targeting.

Qiang M, Chen Z, Liu H, Dong J, Gong K, Zhang X Front Pharmacol. 2025; 16:1516583.

PMID: 40041495 PMC: 11877449. DOI: 10.3389/fphar.2025.1516583.

Drug development and evidence for lung cancer targeted therapy in Eastern Asia.

Liu S, Jin Z, Deng J, Zhong S, Ahn M, Horinouchi H Lancet Reg Health West Pac. 2024; 49:101090.

PMID: 39381018 PMC: 11459064. DOI: 10.1016/j.lanwpc.2024.101090.

Precision Oncology Clinical Trials: A Systematic Review of Phase II Clinical Trials with Biomarker-Driven, Adaptive Design.

Ha H, Lee H, Kim J, Kim D, An H, Bae S Cancer Res Treat. 2024; 56(4):991-1013.

PMID: 38726510 PMC: 11491240. DOI: 10.4143/crt.2024.128.

Inferring evolutionary trajectories from cross-sectional transcriptomic data to mirror lung adenocarcinoma progression.

Huang K, Zhang Y, Gong H, Qiao Z, Wang T, Zhao W PLoS Comput Biol. 2023; 19(5):e1011122.

PMID: 37228122 PMC: 10246837. DOI: 10.1371/journal.pcbi.1011122.

Unlocking multidimensional cancer therapeutics using geometric data science.

Parashar D Sci Rep. 2023; 13(1):8255.

PMID: 37217528 PMC: 10202902. DOI: 10.1038/s41598-023-34853-x.

References

Shaw R, Bardeesy N, Manning B, Lopez L, Kosmatka M, DePinho R . The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell. 2004; 6(1):91-9. DOI: 10.1016/j.ccr.2004.06.007. View

She Q, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T . 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell. 2010; 18(1):39-51. PMC: 3286650. DOI: 10.1016/j.ccr.2010.05.023. View

Pike K, Malagu K, Hummersone M, Menear K, Duggan H, Gomez S . Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. Bioorg Med Chem Lett. 2013; 23(5):1212-6. DOI: 10.1016/j.bmcl.2013.01.019. View

Wagle N, Grabiner B, Van Allen E, Amin-Mansour A, Taylor-Weiner A, Rosenberg M . Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014; 371(15):1426-33. PMC: 4564868. DOI: 10.1056/NEJMoa1403352. View

. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012; 489(7417):519-25. PMC: 3466113. DOI: 10.1038/nature11404. View

Lynch T, Bell D, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan B . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350(21):2129-39. DOI: 10.1056/NEJMoa040938. View

Davies B, Greenwood H, Dudley P, Crafter C, Yu D, Zhang J . Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012; 11(4):873-87. DOI: 10.1158/1535-7163.MCT-11-0824-T. View

Puyol M, Martin A, Dubus P, Mulero F, Pizcueta P, Khan G . A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell. 2010; 18(1):63-73. DOI: 10.1016/j.ccr.2010.05.025. View

Shaw A, Ou S, Bang Y, Camidge D, Solomon B, Salgia R . Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014; 371(21):1963-71. PMC: 4264527. DOI: 10.1056/NEJMoa1406766. View

10.

Gao Y, Xiao Q, Ma H, Li L, Liu J, Feng Y . LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proc Natl Acad Sci U S A. 2010; 107(44):18892-7. PMC: 2973865. DOI: 10.1073/pnas.1004952107. View

11.

Ohashi K, Sequist L, Arcila M, Lovly C, Chen X, Rudin C . Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res. 2013; 19(9):2584-91. PMC: 3643999. DOI: 10.1158/1078-0432.CCR-12-3173. View

12.

. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511(7511):543-50. PMC: 4231481. DOI: 10.1038/nature13385. View

13.

Dibble C, Asara J, Manning B . Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol. 2009; 29(21):5657-70. PMC: 2772744. DOI: 10.1128/MCB.00735-09. View

14.

Ye X, Zerlanko B, Kennedy A, Banumathy G, Zhang R, Adams P . Downregulation of Wnt signaling is a trigger for formation of facultative heterochromatin and onset of cell senescence in primary human cells. Mol Cell. 2007; 27(2):183-196. PMC: 2698096. DOI: 10.1016/j.molcel.2007.05.034. View

15.

Paik P, Shen R, Berger M, Ferry D, Soria J, Mathewson A . A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers. Clin Cancer Res. 2017; 23(18):5366-5373. PMC: 5600836. DOI: 10.1158/1078-0432.CCR-17-0645. View

16.

Thress K, Paweletz C, Felip E, Cho B, Stetson D, Dougherty B . Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015; 21(6):560-2. PMC: 4771182. DOI: 10.1038/nm.3854. View

17.

Janne P, Shaw A, Pereira J, Jeannin G, Vansteenkiste J, Barrios C . Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2012; 14(1):38-47. DOI: 10.1016/S1470-2045(12)70489-8. View

18.

Scheffler M, Bos M, Gardizi M, Konig K, Michels S, Fassunke J . PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies. Oncotarget. 2014; 6(2):1315-26. PMC: 4359235. DOI: 10.18632/oncotarget.2834. View

19.

Spoerke J, OBrien C, Huw L, Koeppen H, Fridlyand J, Brachmann R . Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res. 2012; 18(24):6771-83. DOI: 10.1158/1078-0432.CCR-12-2347. View

20.

Janne P, Yang J, Kim D, Planchard D, Ohe Y, Ramalingam S . AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015; 372(18):1689-99. DOI: 10.1056/NEJMoa1411817. View